This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
TruBridge Performance degli utili passati
Criteri Il passato verificati 1/6
Gli utili di TruBridge sono diminuiti a un tasso medio annuo di -42.1%, mentre il settore Healthcare Services ha visto gli utili crescere a un tasso medio annuo di 21.6%. I ricavi sono cresciuti crescere a un tasso medio annuo di 5.1%. Il ritorno sul capitale proprio di TruBridge è 2.5% e ha margini netti di 1.2%.
Informazioni chiave
-42.11%
Tasso di crescita degli utili
-42.16%
Tasso di crescita dell'EPS
| Healthcare Services Crescita del settore | 1.72% |
| Tasso di crescita dei ricavi | 5.11% |
| Rendimento del capitale proprio | 2.46% |
| Margine netto | 1.23% |
| Ultimo aggiornamento sugli utili | 31 Mar 2026 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Aggiornamento narrativa • Jul 10
TBRG: IKS Deal, Legal Probes And Reclassified Outlook Will Shape Re Rating
Analysts have lifted the TruBridge price target from $22.00 to about $25.44, citing updated assumptions around revenue growth, profit margins and a lower P/E multiple. This view is supported by recent research that includes both price target increases and rating downgrades, as well as commentary on the potential IKS acquisition.
Aggiornamento narrativa • Jun 26
TBRG: Pending IKS Buyout Will Likely Expose Execution Risks
The analyst price target for TruBridge has moved from $15 to $23. Analysts attribute this change to adjustments in fair value assumptions, a lower discount rate, and updated expectations for revenue growth, profit margins, and future P/E.Aggiornamento narrativa • Apr 17
TBRG: Potential IKS Deal And EHR Execution Will Shape Future Re Rating
TruBridge's analyst fair value estimate has shifted from $21.00 to $22.00 as analysts update their models around potential IKS-related opportunities, as well as recent mixed price target moves across the Street. Analyst Commentary Bullish Takeaways Bullish analysts point to the potential IKS transaction as aligned with TruBridge's ongoing review of its business.
Nuova narrativa • Apr 16
AI And Global Delivery Expansion Will Reshape Rural Hospital Solutions Over The Next Decade
Catalysts About TruBridge TruBridge provides revenue cycle, financial health and patient care software and services to hospitals, with a focus on rural and community facilities. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Apr 14
TruBridge: Potential Takeover Target, Upside Fundamentally Supported
Summary TruBridge, Inc. is undergoing an operational turnaround with margin expansion, rising EBITDA, and a shift to high-quality recurring revenue. A potential $600 million takeover by Inventurus Knowledge Systems offers a 36–40% premium to current prices but introduces binary deal risk. TBRG’s recurring revenue remains high at 94%, with stable cash flows and improved profitability despite flat top-line growth. The implied takeover valuation aligns with sector multiples, suggesting the upside is fundamentally supported, not purely speculative. Read the full article on Seeking AlphaAggiornamento narrativa • Apr 02
TBRG: Revenue Cycle Momentum And EHR Stability Will Support Future Re Rating
Analysts have trimmed their price targets on TruBridge, with the average moving from about $22.67 to $21.00 as they weigh a slightly higher discount rate, modestly different revenue growth and margin assumptions, and a lower future P/E multiple against the company's mix of Revenue Cycle Management growth potential and stable Electronic Health Records operations. Analyst Commentary Recent research updates on TruBridge reflect a mix of optimism around the business model and caution around execution and valuation.Nuova narrativa • Apr 02
AI Expansion And Global Delivery Shift Will Shape A Steady But Capped Future
Catalysts About TruBridge TruBridge provides revenue cycle, financial health and electronic health record solutions to hospitals and healthcare providers, with a particular focus on rural and community facilities. What are the underlying business or industry changes driving this perspective?Articolo di analisi • Feb 12
Returns At TruBridge (NASDAQ:TBRG) Appear To Be Weighed Down
What are the early trends we should look for to identify a stock that could multiply in value over the long term...Aggiornamento narrativa • Jan 28
TBRG: Revenue Cycle Focus And EHR Stability Will Test Execution Outcomes
Narrative Update The analyst price target for TruBridge has shifted modestly higher to about $22.67 per share, supported by analysts citing the potential of its Revenue Cycle Management focus alongside a steadier Electronic Health Records business, while still calling out execution risk after recent periods of low growth. Analyst Commentary Recent research points to a mixed but constructive view on TruBridge, with analysts focusing on the shift toward Revenue Cycle Management and the steadier Electronic Health Records business when considering valuation and execution risk.Aggiornamento narrativa • Jan 12
TBRG: Revenue Cycle Realignment And EHR Stability Will Require Steady Execution
Narrative Update The analyst price target for TruBridge now centers around US$23, a modest lift from the prior US$22.60. Analysts point to the potential of the Revenue Cycle Management opportunity alongside a steadier Electronic Health Records business, while still flagging execution risk after recent periods of low growth.Aggiornamento narrativa • Dec 17
TBRG: Revenue Cycle Shift Will Demand Proven Execution Before Rerating
Analysts raised their price target on TruBridge modestly, citing improving growth prospects from the company’s shift toward revenue cycle management as evidence builds of its long-term earnings potential. Analyst Commentary Bullish Takeaways Bullish analysts view the company’s realignment toward revenue cycle management as a structurally higher growth opportunity compared with its legacy clinical software offerings.Aggiornamento narrativa • Dec 03
TBRG: Revenue Cycle Pivot Will Require Clear Execution Evidence In 2025
Analysts have nudged their price target on TruBridge slightly higher to approximately $22.60 per share. This reflects increased confidence that the company’s shift toward revenue cycle management can unlock more attractive, evidence-based growth than its legacy clinical software focus.Aggiornamento narrativa • Nov 19
TBRG: Measured Optimism Will Depend On Evidence Of Execution In 2025
TruBridge's analyst price target has been revised downward from $24.75 to $22.60. Analysts cite recent coverage reflecting cautious optimism about the company's strategic shift toward revenue cycle management, while awaiting clearer evidence of execution before turning more positive.Articolo di analisi • Nov 14
Solid Earnings Reflect TruBridge's (NASDAQ:TBRG) Strength As A Business
Even though TruBridge, Inc.'s ( NASDAQ:TBRG ) recent earnings release was robust, the market didn't seem to notice. We...Aggiornamento narrativa • Aug 15
AI And India Hub Will Boost Future Healthcare Efficiency
Despite a notable improvement in TruBridge’s net profit margin and a significant decline in its future P/E ratio, the consensus analyst price target has been sharply revised down from $29.25 to $24.75. What's in the News TruBridge lowered its full-year 2025 revenue guidance to $345 million-$350 million from a previous range of $345 million-$360 million; third quarter 2025 revenue is forecasted at $85 million-$87 million.Nuova narrativa • May 31
Digital Automation And AI Will Drive Healthcare Transformation
Increased AI-driven automation, expanded SaaS offerings, and digital transformation are expected to boost operational efficiency, recurring revenue growth, and earnings quality.Articolo di analisi • Feb 14
Would TruBridge (NASDAQ:TBRG) Be Better Off With Less Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Articolo di analisi • Jan 17
TruBridge, Inc. (NASDAQ:TBRG) Shares Fly 27% But Investors Aren't Buying For Growth
TruBridge, Inc. ( NASDAQ:TBRG ) shares have continued their recent momentum with a 27% gain in the last month alone...Articolo di analisi • Nov 13
TruBridge, Inc.'s (NASDAQ:TBRG) Business And Shares Still Trailing The Industry
TruBridge, Inc.'s ( NASDAQ:TBRG ) price-to-sales (or "P/S") ratio of 0.7x might make it look like a buy right now...Ripartizione dei ricavi e delle spese
Ripartizione dei ricavi e delle spese
Come TruBridge guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storico di utili e ricavi
| Data | Ricavi | Utili | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 31 Mar 26 | 346 | 4 | 105 | 32 |
| 31 Dec 25 | 347 | 4 | 100 | 33 |
| 30 Sep 25 | 347 | 3 | 101 | 33 |
| 30 Jun 25 | 345 | -11 | 101 | 33 |
| 31 Mar 25 | 345 | -18 | 98 | 33 |
| 31 Dec 24 | 342 | -20 | 96 | 35 |
| 30 Sep 24 | 337 | -59 | 86 | 37 |
| 30 Jun 24 | 335 | -54 | 77 | 39 |
| 31 Mar 24 | 334 | -52 | 84 | 40 |
| 31 Dec 23 | 337 | -47 | 104 | 39 |
| 30 Sep 23 | 337 | -1 | 80 | 36 |
| 30 Jun 23 | 337 | 5 | 88 | 33 |
| 31 Mar 23 | 335 | 11 | 81 | 32 |
| 31 Dec 22 | 327 | 16 | 78 | 32 |
| 30 Sep 22 | 317 | 18 | 77 | 31 |
| 30 Jun 22 | 305 | 19 | 76 | 32 |
| 31 Mar 22 | 290 | 22 | 71 | 30 |
| 31 Dec 21 | 281 | 18 | 70 | 33 |
| 30 Sep 21 | 273 | 16 | 71 | 31 |
| 30 Jun 21 | 272 | 18 | 69 | 32 |
| 31 Mar 21 | 263 | 14 | 70 | 34 |
| 31 Dec 20 | 264 | 14 | 70 | 33 |
| 30 Sep 20 | 268 | 22 | 68 | 34 |
| 30 Jun 20 | 269 | 20 | 68 | 35 |
| 31 Mar 20 | 275 | 20 | 71 | 36 |
| 31 Dec 19 | 275 | 20 | 71 | 37 |
| 30 Sep 19 | 276 | 16 | 75 | 37 |
| 30 Jun 19 | 277 | 18 | 76 | 37 |
| 31 Mar 19 | 279 | 17 | 77 | 37 |
| 31 Dec 18 | 280 | 17 | 78 | 36 |
| 30 Sep 18 | 286 | -11 | 82 | 36 |
| 30 Jun 18 | 284 | -15 | 81 | 35 |
| 31 Mar 18 | 284 | -13 | 81 | 34 |
| 31 Dec 17 | 277 | -17 | 80 | 34 |
| 30 Sep 17 | 263 | 6 | 75 | 34 |
| 30 Jun 17 | 261 | 5 | 75 | 34 |
| 31 Mar 17 | 262 | 6 | 73 | 34 |
| 31 Dec 16 | 267 | 4 | 72 | 29 |
| 30 Sep 16 | 247 | 5 | 63 | 27 |
| 30 Jun 16 | 227 | 7 | 61 | 22 |
| 31 Mar 16 | 206 | 11 | 55 | 18 |
| 31 Dec 15 | 182 | 18 | 52 | 14 |
| 30 Sep 15 | 184 | 21 | 50 | 11 |
Guadagni di qualità: TBRG ha un grande una tantum perdita di $10.0M che ha avuto un impatto sui suoi ultimi 12 mesi di risultati finanziari pari a 31st March, 2026.
Margine di profitto in crescita: TBRG è diventata redditizia in passato.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: Gli utili di TBRG sono diminuiti del 42.1% all'anno negli ultimi 5 anni.
Accelerare la crescita: TBRG è diventata redditizia nell'ultimo anno, rendendo difficile confrontare il tasso di crescita degli utili con la media quinquennale.
Guadagni vs Settore: TBRG è diventata redditizia nell'ultimo anno, rendendo difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Healthcare Services ( 12.4% ).
Rendimento del capitale proprio
ROE elevato: Il Return on Equity ( 2.5% ) di TBRG è considerato basso.
Rendimento delle attività
Rendimento del capitale investito
Scoprire le aziende con forti performance passate
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/07/10 16:31 |
| Prezzo dell'azione a fine giornata | 2026/07/08 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
TruBridge, Inc. è coperta da 22 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Matthew Gillmor | Baird |
| Stephanie Davis | Barclays |
| Sean Dodge | BMO Capital Markets Equity Research |